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Abstract
Background: Although women of reproductive age are the largest group of HIV-infected individuals in sub-Saharan Africa,
little is known about the impact of pregnancy on response to highly active antiretroviral therapy (HAART) in that setting. We
examined the effect of incident pregnancy after HAART initiation on virologic response to HAART.
Methods and Findings: We evaluated a prospective clinical cohort of adult women who initiated HAART in Johannesburg,
South Africa between 1 April 2004 and 30 September 2009, and followed up until an event, death, transfer, drop-out, or
administrative end of follow-up on 31 March 2010. Women over age 45 and women who were pregnant at HAART initiation
were excluded from the study; final sample size for analysis was 5,494 women. Main exposure was incident pregnancy,
experienced by 541 women; main outcome was virologic failure, defined as a failure to suppress virus to #400 copies/ml by
six months or virologic rebound .400 copies/ml thereafter. We calculated adjusted hazard ratios using marginal structural
Cox proportional hazards models and weighted lifetable analysis to calculate adjusted five-year risk differences. The
weighted hazard ratio for the effect of pregnancy on time to virologic failure was 1.34 (95% confidence limit [CL] 1.02, 1.78).
Sensitivity analyses generally confirmed these main results.
Conclusions: Incident pregnancy after HAART initiation was associated with modest increases in both relative and absolute
risks of virologic failure, although uncontrolled confounding cannot be ruled out. Nonetheless, these results reinforce that
family planning is an essential part of care for HIV-positive women in sub-Saharan Africa. More work is needed to confirm
these findings and to explore specific etiologic pathways by which such effects may operate.
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Introduction
The largest group of individuals living with HIV in Africa are
women of child-bearing age [1]. In South Africa, young women
have more than three times the estimated prevalence of HIV
infection compared with young men [2,3]. Furthermore, preva-
lence of HIV among pregnant women in South Africa was
estimated at 28% in 2007, and may be as high as 40% among
pregnant women ages 30–34: substantially higher than the overall
adult prevalence [3]. In South Africa, antenatal testing is a key
way in which women receive an HIV diagnosis; as such,
pregnancy is a common indication for the initiation of highly
active antiretroviral therapy (HAART) for the prevention of
mother to child transmission [4]. Pregnancy is also common after
clinically indicated initiation of HAART [5,6].
Numerous studies have focused on optimal methods for
prevention of mother to child transmission of HIV and subsequent
response to HAART [7,8,9,10,11,12,13], as well as issues of fertility
during HAART [14]. There is likewise a long history of studies
examiningtheeffect ofpregnancyonHIVdiseaseprogressioninthe
pre-HAART era [15,16,17,18,19] and a growing body of research
on the impact of pregnancy on response to HAART in higher
incomecountries[20,21,22,23,24].However, todate therehasbeen
very little research examining effects of pregnancy on maternal
response to HAART in sub-Saharan Africa [25]. This relative
absence of evidence is striking given the unequivocal statement by
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in decisions about ARV treatment during pregnancy’’ [26].
There are a number of reasons to hypothesize that response to
HAART may be compromised during pregnancy. Pregnancy is
associated with increases in blood volume and body mass index,
which may lead to underdosing of drugs [27,28]. Levels of
cytochrome p450, and in particular CYP3A isoenzymes, may rise
during pregnancy [29], increasing the metabolism of two
antiretroviral drugs often given to HIV-positive pregnant women,
lopinavir and nevirapine; thus pregnant women may experience
reduced concentrations of both drugs [27,29,30,31]. Additionally,
beta-estradiol levels increase substantially in pregnancy [6,32];
beta-estradiol may attenuate the efficacy of stavudine [32],
another component of first-line HAART in South Africa. Last,
social pressures related to pregnancy including stigma and fear of
intimate partner violence [25], as well as responsibilities of new
motherhood, may compromise adherence to HAART and thus
virologic response to therapy. We thus hypothesized that
pregnancy increases risk of virologic failure.
Much remains unknown about both short- and long-term risks
associated with pregnancy in HIV-positive women receiving
HAART, especially in sub-Saharan Africa. With large numbers
of HIV-positive women becoming pregnant [14], it is vital to
understand the impact of pregnancy on virologic outcomes of
HAART.
Materials and Methods
Ethics statement
This research was based on de-identified previously collected
clinical records, and was declared exempt from human subjects
review by the University of the Witwatersrand, the University of
North Carolina at Chapel Hill, and Duke University.
Study population and design
We performed a prospective observational cohort study in the
database of the Themba Lethu Clinic [33]. The Themba Lethu
Clinic (henceforth, TLC) Cohort is a study of adults initiating
HAART in Johannesburg, South Africa. The program is funded
by the South African National and Gauteng Department of
Health, with support from Right to Care and funding by USAID
and PEPFAR. The TLC, sited at the regional Helen Joseph
Hospital in urban Johannesburg, has over 17,000 patients in care
and is the largest single clinic providing HAART in South Africa,
and one of the largest HAART clinics worldwide. We studied
previously antiretroviral therapy-naı ¨ve women from the time of
HAART initiation between 1 April 2004 and 30 September 2009
at TLC. We followed these women until they experienced an
outcome, administrative end of follow-up on 31 March 2010, or
the end of care due to drop-out, death, or transfer of care to
another site. Additional exclusions (by age and baseline pregnancy
status) are described below.
Typical first-line HAART included stavudine, lamivudine, and
efavirenz. Due to concerns about teratogenicity, women found to
be pregnant are typically placed on the boosted protease inhibitor
Kaletra (lopinavir and ritonavir) rather than efavirenz, while non-
pregnant women with declared pregnancy intention at baseline are
placed on nevirapine or Kaletra rather than efavirenz. Additional
details of the TLC clinical database, clinic procedures, and
outcomes have been described previously [33,34,35]. Here, we
note that clinical data are captured prospectively in the TLC and
that accuracy of data entry has been previously validated [33].
However, subjects did not receive care for pregnancy in the TLC,
and thus data on fetal outcomes are not available.
Definitions and data
The main exposure in this study was ‘‘ever became pregnant
after HAART initiation’’; that is, an incident pregnancy occurring
subsequent to HAART initiation, regardless of length and
outcome of the pregnancy. Pregnancy was defined based on
clinical finding of pregnancy recorded in the clinical database in
the course of standard HIV care. We concentrated on incident
rather than prevalent pregnancy (i.e., pregnancy ongoing at the
time of HAART initiation) due to concerns about confounding by
indication. Women with prevalent pregnancy often initiate
HAART because they are pregnant, and thus may be systematically
different than women who initiate HAART for their own health
and later become pregnant. Thus, women with prevalent
pregnancy might be in general healthier than other women; this
might manifest in a greater resiliency to drug toxicities or differing
adherence to HAART which would obscure the effect of
pregnancy itself. To avoid this bias, we excluded women who
were prevalent at baseline from the main analysis, employing a
‘‘new pregnancy design’’ similar to the ‘‘new-user design’’ of
pharmacoepidemiology [36]. Alternative exposure definitions
were explored in sensitivity analysis.
The main outcome in this study was virologic failure, which was
defined following Riddler et al. [37] as either a failure to achieve
virologic suppression of plasma HIV-1 RNA to less than 400
copies/ml within six months of HAART initiation, or a viral
rebound to above 400 copies/ml at any time after initial
suppression. Confirmation of outcome by a second viral load test
within 30 days was obtained when possible, but data from patients
missing a confirmatory sample were included as failures [37]. In
the main analysis, both death and drop-out were treated as
censoring conditions; in sensitivity analysis we examined alterna-
tive outcomes and censoring variables.
Adherence to HAART was estimated from pharmacy records,
as the time-updated cumulative proportion of days between
pharmacy visits in which a subject had antiretroviral drugs
available, included in regression models as a three-category
variable (,95%, 95–99.9%, 100%). This estimate of adherence
is an upper limit on potential adherence, because drugs can only be
taken correctly if they are available.
Statistical analysis
As noted above, the main analysis focused on the effect of
incident pregnancy on time to virologic failure. A key concern of
this analysis was the possibility of time-varying confounding
affected by prior exposure [38,39]. Thus, in addition to time-
updated adjusted Cox models, we also used marginal structural
Cox proportional hazards models [38,39] to estimate hazard ratios
(HRs), as well as confounding-adjusted extended Kaplan-Meier
curves [40]. In both these cases, inverse probability weights were
used to account for bias due to both confounding [41] and drop-
out [38]. In the main analysis, weights were truncated at the 1
st
and 99
th percentile to reduce the variance of estimates [42]. We
used crude Kaplan-Meier curves to estimate crude five-year risk
differences with confidence intervals derived from 200 bootstraps
of the data.
In all multivariable analyses, we considered the following
confounders of the effect of pregnancy on time to virologic failure,
based on previous literature and biological mechanism. Con-
founders measured at baseline (HAART initiation) included age,
ethnicity, employment status, current tuberculosis, calendar date
of HAART initiation, history of smoking, and WHO stage.
Confounders measured over time included weight, body mass
index, hemoglobin, CD4 count and CD4 percent, antiretroviral
drug regimen, and drug adherence. We used restricted cubic
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and time-on-study. Drug regimen was lagged by three months to
ensure that we controlled for drug changes preceding pregnancy,
rather than changes in drug regimen affected by pregnancy. We did
not control for baseline viral load because it is collected in less than
25% of participants.
Sensitivity analysis and missing data
To test analytic assumptions, we performed several sensitivity
analyses in addition to the main analysis; these sensitivity analyses
addressed issues in definitions of the population, exposure, and
outcome, as well as technical decisions in the modeling.
We restricted the population to those women who had
suppressed virus by six months after HAART initiation, and
looked at subsequent incident pregnancy and virologic failure
(sensitivity analysis 1). We considered a more inclusive definition of
prevalent pregnancy for exclusion from the study population,
based on initial drug regimen as well as database-recorded
pregnancy status, to ensure that undercounting of prevalent
pregnancy was not a source of bias (2). We examined the effect of
pregnancy on less-specific outcomes, namely virologic failure or
mortality (3), and virologic failure, mortality, or drop-out (4). We
also examined a more restrictive outcome, in which we considered
virologic failures only if they were confirmed within 30 days (5). We
combined analyses 1 and 5, restricting to those with initial
suppression who also had confirmed virologic failure (6). We
considered an exposure of prevalent and incident pregnancy
together, abandoning the ‘‘new-user’’ design described above (7).
In all analyses, longitudinal data were carried forward from the
most recent observed value. Missing data led to approximately 9%
missing observations in the final analysis. The last two sensitivity
analyses used a multiple imputation analysis to account for missing
data (8), and in dropped carry-forward of time-updated variables
(9).
Role of the funding source
The funding sources had no involvement in the design or
conduct of the study, in the collection, management, analysis, or
interpretation of the data, in the preparation, writing, review or
approval of this manuscript, or in the decision to submit this
manuscript for publication.
Results
The initial study population comprised 7,181 women at time of
HAART initiation. After exploring univariate distributions of age
by baseline pregnancy status, we excluded women who were over
age 45 at baseline (1 pregnant woman, 1,138 non-pregnant
women) to improve comparability and interpretability of final
effect estimates [43]. This left 6,042 women; excluding 548 (9%)
women who were pregnant at time of HAART initiation yielded a
total sample size for the main analysis of 5,494 women of whom
541 experienced an incident pregnancy during follow-up. These
5,494 women contributed a total of approximately 11,600 person-
years (139,272 person-months) to this analysis, of which 11,826
person-months (8.5%) were exposed, occurring coincident with or
subsequent to an incident pregnancy. Median follow-up time in all
women was 18 (IQR 9, 37) months.
Baseline characteristics of the 5,494 subjects are given described
in Table 1; in addition, Table 1 shows baseline and time-updated
characteristics of the subset of 541 women who experienced an
incident pregnancy. In general, at time of incident pregnancy,
women were healthier than the average woman at time of HAART
initiation, with a higher CD4 count, hemoglobin, and body mass
index (BMI). At the time of incident pregnancy, the vast majority of
women(94%)had asuppressedviralload.AgeatHAARTinitiation
was among the strongest predictors of both baseline and incidence
pregnancy (Figure 1). Of note, an estimated 44% (95% confidence
limits [CL] 36, 54%) of women who were 18–25 years old at the
time of HAART initiation experience incident pregnancy within
four years HAART initiation in this cohort.
Table 1. Characteristics of 5,494 women at time of HAART
initiation, and a subpopulation of 541 of those women at time
of incident pregnancy, in Johannesburg, South Africa from 1
April 2004 to 30 September 2009.
Demographics
At baseline
(n=5,494)
At incident
pregnancy
(n=541)
Age years 34 (29, 38) 32 (28, 35)
African ethnicity 5,293 (96.3) 531 (98.2)*
Employed 2,233 (40.6) 216 (40.0)*
History of smoking 269 (4.9) 21 (3.9)*
Clinical
HAART regimen
d4t-3TC-EFV 4580 (83.4) 222 (41.0)
d4t-3TC-NVP 473 (8.6) 81 (15.0)
d4t-3TC-LPVr 146 (2.7) 116 (21.4)
Weight kilograms 57 (49, 65) 64 (56, 73)
Body mass index kg/m
2 22.2 (19.5, 25.5) 24.8 (21.9, 27.7)
Body mass index category kg/m
2
,18.5 930 (17.7) 22 (4.1)
18.5–24.9 2,845 (54.2) 260 (48.3)
25.0–29.9 987 (18.8) 172 (32.0)
$30 488 (9.3) 84 (15.6)
WHO stage III or IV 2,369 (43.1) 235 (43.4)*
Current tuberculosis 963 (17.5) 88 (16.3)*
Laboratory
Hemoglobin, low
{ 2,914 (54.7) 113 (21.1)
CD4 count cells/mm
3 93 (35, 164) 304 (189, 433)
CD4 count category cells/mm
3
#50 1,736 (32.6) 18 (3.3)
51–100 1,075 (20.2) 22 (4.1)
101–200 1,864 (35.0) 112 (20.8)
201–350 521 (9.8) 167 (31.0)
.350 133 (2.5) 220 (40.8)
Viral load
{ log copies/ml 4.2 (3.4, 4.6) 1.7 (1.7, 1.7)
Viral load category log copies/ml
#400 308 (20.0) 444 (93.9)
401–10000 251 (16.3) 10 (2.1)
.10000 984 (63.8) 19 (4.0)
d4T: stavudine. 3TC: lamivudine. EFV: efavirenz. NVP: nevirapine. LPVr:
Lopinavir-ritonavir (Kaletra). Categorical variables are expressed as number (%
of total non-missing); continuous variables are expressed as median
(interquartile range).
*These measures are baseline measures, not updated to time of incident
pregnancy.
{After adjustment for altitude, lower limit of normal hemoglobin is 11.35 g/dl.
{Baseline viral load was missing in 3951 (72%) women at baseline, and in 68 of
women at time of exposure.
doi:10.1371/journal.pone.0022778.t001
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including efavirenz (83% were on the standard first-line HAART
regimenofstavudine,lamivudine,andefavirenz),suggestingalackof
intention to becomepregnant;431ofthesewomen later experienced
a pregnancy. At the time of incident pregnancy, fewer women (53%)
were receiving efavirenz. Many of these women switched to non-
efavirenz-based HAART during pregnancy: 38% remained on
efavirenz by month 3 of pregnancy. By month 5 of pregnancy, only
27% remained on efavirenz, the same proportion as remained on
efavirenz at 9 months. By 18 months after conception, the
proportion receiving efavirenz had risen back to 55%.
Of the 5,494 women considered in the main analysis, 81 women
experienced virologic failure after an incident pregnancy (15% of
the 541 exposed women); 748 (15%) of non-pregnant women
experienced this outcome. Of the 829 total failures analyzed in
main analysis, only 52 were confirmed within 30 days and 140
within 60 days. Examining all potential failures (not just those
included in main analysis), 189 women had any virologic failure
which was confirmed within 30 days. About one-third (n=253) of
total virologic failures were a failure to suppress within six months;
the remaining two-thirds occurred after six months. Before
experiencing the outcome or administrative censoring, 50
pregnant women (9%) died or dropped out, compared with
1680 (34%) non-pregnant women.
In the main analysis, the crude HR for the total effect of
incident pregnancy on time to virologic failure over all of follow-up
was 1.37 (95% CL 1.08, 1.73); the adjusted was 1.35 (95% CL
1.03, 1.77); and the weighted HR was 1.34 (95% CL 1.02, 1.78)
(Table 2). The crude estimated absolute difference for the total
effect of incident pregnancy on 5-year risk of virologic failure was
0.06 (20.02, 0.14), an estimated 6% increase in virologic failure by
five years. Figure 2 shows the crude and weighted extended
Kaplan-Meier curves for the effect of pregnancy on time to
virologic failure.
Among women who experienced a pregnancy, virologic failure
was more common during pregnancy than after pregnancy; of the 81
failures observed, 42 took place during the nine months following
reported start of pregnancy and 39 took place thereafter. A time-
adjusted crude rate ratio comparing failure rate during the 9
months of the incident pregnancy exposure compared to other
times was 1.49 (95% CL 1.09, 2.03), slightly stronger than the
crude main effect estimate; likewise, the weighted rate ratio was
slightly further from the null at 1.42 (95% CL 1.00, 2.01).
An additional, predictive (non-causal) analysis was undertaken
to characterize the associations of baseline and time-updated
variables on risk of the outcome (Table 3). To increase
interpretability of these predictive factors, this analysis used less-
flexible categorical parameterizations of BMI and CD4 count, and
Figure 1. Crude cumulative incidence of pregnancy since date of HAART initiation, stratified by baseline age among 5,494 HIV-
positive women initiating HAART in Johannesburg, South Africa from 1 April 2004 to 30 September 2009.
doi:10.1371/journal.pone.0022778.g001
Pregnancy and Response to Antiretroviral Therapy
PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e22778controlled for confounding only by time-updated measures of risk
factors. As a result, the adjusted hazard ratio for pregnancy itself
from this model was biased, and was therefore excluded from
Table 3. This model showed that older age, baseline employment
status, and lower BMI were associated with lower HR for virologic
failure; and that lower CD4 count, use of nevirapine (compared
with efavirenz), and less-than-perfect adherence were associated
with higher HRs for virologic failure.
Results from sensitivity analyses are summarized in Table S1.
Restriction to women who had suppressed virus by six months
(and who had not yet experienced pregnancy by that point) yielded
a point estimate similar but less precise than the main effect:
HR=1.39 (95% CL 0.97, 1.99) (analysis 1, Table S1). The
exclusions of additional women suspected of being pregnant at
baseline likewise had little effect on the estimate of effect (analysis
2). In general, as the outcome and exposure became less strictly
defined (analyses 3, 4, 7) the hazard ratio moved toward or to the
null; most notably, when the outcome was failure, drop-out, or
death, the point estimate was 0.96 (95% CL 0.78, 1.17). When
outcome was more strictly defined, as any virologic failure
confirmed within 30 days (analysis 5; starting with the 189
virologic failures described above), results were stronger but less
precise (HR=1.43, 95% CL 0.80, 2.55); results were similar when
allowing a 60-day confirmation window. Restricting to women
with both initial virologic suppression and confirmed virologic
failure (analysis 6; total 101 outcomes) yielded an estimate
somewhat closer to the null and much less precise, compared
with the main result. The multiple imputation analysis (10
imputations, analysis 8) yielded a point estimate slightly closer to
the null (HR=1.27), as did dropping the ‘‘carry-forward’’ of time-
updated variables (analysis 9, HR=1.25).
Discussion
In this observational study of HIV-positive women initiating
HAART in South Africa, we found that incident pregnancy after
HAART initiation is associated with increased relative and
absolute risk of virologic failure of therapy during follow-up.
Our main analysis estimated that pregnancy is associated with a
hazard ratio of 1.34 (95% CL 1.02, 1.78), and an estimated
absolute 6% increase in virologic failure by five years of follow-up.
Our results were stronger when the question being examined
was more specific, and weaker when the question was more broad.
In the former case, restricting to the period of pregnancy itself
(rather than time after pregnancy) yielded an incidence rate ratio
further from the null than main results; so did analyzing only
confirmed virologic failures. In contrast, as the definitions of
exposure and outcome used in the main analysis (incident
pregnancy only as the exposure; virologic failure only as the
Table 2. Estimated effect of incident pregnancy on time to
virologic failure among 5,494 women initiating HAART in
South Africa, 2004–2009.
No. of events
Person-months
of follow-up HR 95% CL
Unadjusted
Not pregnant 748 127,446 1.
Pregnant 81 11,826 1.37 1.08, 1.73
Adjusted{ 1.35 1.03, 1.77
Weighted{
Not pregnant 675{ 115,376 1.
Pregnant 67{ 9,650 1.34 1.02, 1.78
HR, hazard ratio; CL, confidence limit.
{Both standard adjusted and weighted models accounted for the same set of
covariates, namely age, ethnicity, history of smoking, employment status,
active tuberculosis at study entry, calendar date at entry, WHO stage, and time-
updated weight, body mass index, hemoglobin, CD4 count and percent, drug
regimen, and drug adherence.
{Weighted event and person-month counts are given. Unweighted, these
numbers are 688/116,884 and 69/9,918.
doi:10.1371/journal.pone.0022778.t002
Figure 2. Crude and weighted cumulative incidence curves for the effect of pregnancy on time to virologic failure among 5,494
HIV-positive women initiating HAART in Johannesburg, South Africa from 1 April 2004 to 30 September 2009. Sample sizes in
weighted curves are weighted sample sizes.
doi:10.1371/journal.pone.0022778.g002
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pregnancy together as exposure; virologic failure and death
together as the outcome), effects were generally closer to the null.
Multiple imputation analysis suggested that missing data might
bias these results slightly away from the null, but came to the same
qualitative conclusion as the main analysis.
Despite substantial interest in issues of pregnancy and HIV
disease progression, to date there has been almost no research
performed in populo on the effect of pregnancy on virologic
outcomes of HAART in sub-Saharan Africa, the setting where
such findings are most important. We were able to find only two
previous reports that addressed these issues outside of Africa. This
first study, in the Swiss HIV Cohort, examined 372 pregnancies
among 342 women who started HAART before and during
pregnancy; compared to non-pregnant women, investigators
found no increase in risk of virologic failure, and some indication
of a reduction in risk [22]. A second study, in the United States,
found high incidence of virologic rebound in the early post-partum
period; however, this work examined only 63 women some of
whom initiated HAART during, rather than before, pregnancy
[44]. The generalizability of both studies to sub-Saharan Africa
may be limited due to developed-world settings. The present
study, involving over 11,000 person-years of follow-up in South
Africa, helps fill a significant gap in the literature. Of course, the
replication of this analysis in other sub-Saharan African cohorts is
critical for confirming, or refuting, these findings.
Beyond large sample size, there were several key strengths of
this study. Data were collected prospectively in a previously
validated clinic database [33]. Issues of time-varying confounding
affected by prior treatment were dealt with appropriately, using
marginal structural Cox proportional hazards models [38] and
weighted Kaplan-Meier curves [40]. Unlike in previous analyses
[38,45], a traditionally adjusted regression analysis did not provide
markedly different answers than the marginal structural model.
Nonetheless, the marginal structural model approach is preferred
in situations where such bias may be possible; here, such bias was
possible due to the effect of pregnancy on changes in antiretroviral
therapy regimen, among other factors [46]. Last, previous reports
from this cohort [33,34] suggest that results from the Themba
Lethu Clinic are generally comparable to other cohorts in sub-
Saharan Africa; thus, we believe that the present results will have
good generalizability to (at least) other urban HAART cohorts in
sub-Saharan Africa.
With regard to generalizability, we made two key exclusions in
our main analysis: women pregnant at baseline, and women over
the age of 45. The former group was excluded because of concerns
about confounding and potential selection bias; the latter because
women older than 45 are very unlikely to become pregnant (that
is, to become exposed) and thus present a relatively small group for
whom inference is difficult due to problems of positivity [43]. The
present findings should not be extrapolated to either of these
groups without significant further study.
Other limitations of this study should be noted. We analyzed
observational data from a clinical database, and thus uncontrolled
confounding remains a possible threat to the validity of this study;
for example, data on parity were missing for these subjects.
Another potential confounder is baseline viral load, which was
available in only 25% of women studied; however, restriction to
women who had successfully suppressed virus by six months after
HAART initiation confirmed the main analysis (sensitivity analysis
1), suggesting that this baseline viral load was not a critical source
of bias in this study. Similarly, while we strove to exclude all
women with a history of single-dose nevirapine exposure from our
study, some such women may have been overlooked.
It is also possible that the observed increased rate of virologic
failure after incident pregnancy is the consequence of detection
bias: pregnant women may receive more lab tests than non-
pregnant women. However, compared to non-pregnant women,
the pregnant women were no more likely to have viral load
measured (rate ratio for viral load testing comparing pregnant to
non-pregnant person-time was 1.02, 95% CL 0.97, 1.08) and were
less likely to have CD4 counts measured (rate ratio 0.85, 95% CL
0.81, 0.89). Thus, results are unlikely to be explained by detection
bias.
Last, the interpretation of Table 3 deserves special caution. The
main analysis attempted to obtain an estimate of the causal effect
of pregnancy on time to virologic failure; but no such claims are
made regarding Table 3. Table 3 explicitly represents a predictive,
and not a causal, analysis.
In this study, we estimated the total effect of pregnancy on
virologic failure, rather than direct or indirect effects that might
comprise the total effect. However, estimation of total effects must
be interpreted and generalized with caution; the total effect in this
case includes not only the pregnancy itself, but also the treatments
Table 3. Adjusted hazard ratios for non-causal associations of
selected baseline and time-updated characteristics with time
to virologic failure in 5,494 women initiating HAART in
Johannesburg, South Africa from 1 April 2004 to 30
September 2009.
Time fixed characteristics aHR 95% CL
Baseline age (effect of 5-year increase) 0.89 0.83, 0.94
Employed 0.81 0.70, 0.94
History of smoking 1.33 0.98, 1.79
Baseline tuberculosis 1.09 0.89, 1.33
WHO stage III or IV 1.11 0.95, 1.30
Time updated characteristics aHR 95% CL
Body mass index category kg/m
2
,18.5 0.64 0.40, 1.03
18.5–24.9 0.71 0.52, 0.97
25.0–29.9 0.86 0.67, 1.11
$30 1. NA
Hemoglobin, low
{ grams/dl 1.01 0.85, 1.19
CD4 count category cells/mm
3
#50 5.00 3.60, 6.96
51–100 5.35 3.98, 7.19
101–200 3.57 2.85, 4.49
201–350 2.08 1.69, 2.56
.350 1. NA
Current drug regimen
Efavirenz 1. NA
Nevirapine 1.30 1.04, 1.62
Kaletra 1.17 0.91, 1.50
Adherence
,95% 1.33 1.12, 1.57
95–99.9% 1.22 1.01, 1.46
100% 1. NA
aHR, adjusted hazard ratio. Model controls additionally for incident pregnancy,
time on study, calendar time, weight, and ethnicity.
{After adjustment for altitude, lower limit of normal hemoglobin is 11.35 g/dl.
doi:10.1371/journal.pone.0022778.t003
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and management, and potentially culturally-specific responses to
pregnancy, including stigma and adherence-related behaviors.
Any total effect may in fact conceal heterogeneous mechanisms of
effects. Some aspects of pregnancy (e.g., reduced adherence due to
nausea, interruption or change of antiretroviral drug regimen) may
increase risk of virologic failure, while others (e.g., findings that
high levels of beta-estradiol may result in reduced viral loads
[6,47]) may decrease risk. A related factor, the specific choice of
antiretroviral drugs for pregnant women, might increase or
decrease risks of virologic failure. Future work should explore
these different pathways of effect. In addition, future work should
explore the effect of pregnancy on both clinical and immunolog-
ical outcomes of HAART.
In this large study of clinical cohort data, we found that
pregnancy after HAART initiation modestly increased both
relative and absolute risks of virologic failure. While policy should
never be based on a single study, these results provide more
support [14]_ENREF_14 for the idea that family planning is an
essential part of care and treatment for HIV-positive women in
sub-Saharan Africa.
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